Outcomes
| Outcome . | All patients . | CPI . | No prior CPI . | P value . |
|---|---|---|---|---|
| N = 2186 (95% CI) . | n = 600 (95% CI) . | n = 1586 (95% CI) . | ||
| OS | ||||
| At 100 d | 91% (89-92) | 89% (87-92) | 91% (90-93) | .439 |
| At 6 m | 85% (83-86) | 83% (79-86) | 86% (84-88) | |
| At 12 m | 78% (76-80) | 76% (73-80) | 79% (77-81) | |
| PFS | ||||
| At 100 d | 86% (84-87) | 87% (84-90) | 85% (83-87) | <.001 |
| At 6 m | 74% (72-76) | 78% (75-82) | 72% (70-75) | |
| At 12 m | 61% (58-63) | 69% (65-74) | 58% (55-60) | |
| CI of relapse | ||||
| At 100 d | 7% (6-9) | 4% (3-6) | 9% (7-10) | <.001 |
| At 6 m | 15% (13-17) | 8% (6-10) | 18% (16-20) | |
| At 12 m | 25% (23-27) | 13% (10-16) | 29% (27-32) | |
| NRM | ||||
| At 100 d | 7% (6-8) | 9% (6-11) | 6% (5-8) | .0277 |
| At 6 m | 11% (10-12) | 14% (11-17) | 10% (8-12) | |
| At 12 m | 15% (13-16) | 18% (14-21) | 13% (12-15) | |
| CI of engraftment | ||||
| At 30 d | 97% (96-97) | 96% (94-98) | 97% (96-98) | .3673 |
| At 100 d | 98% (98-99) | 98% (97-99) | 98% (98-99) | |
| aGVHD 2-4∗ | ||||
| At 30 d | 19% (18-21) | 26% (23-30) | 17% (15-19) | <.001 |
| At 100 d | 31% (29-33) | 40% (36-44) | 27% (25-30) | |
| aGVHD 3-4∗ | ||||
| At 30 d | 8% (6-9) | 12% (9-15) | 6% (5-7) | <.001 |
| At 100 d | 11% (10-13) | 16% (13-19) | 9% (8-11) | |
| cGVHD∗ | ||||
| At 100 d | 5% (4-6) | 5% (3-7) | 5% (4-7) | .1514 |
| At 6 m | 21% (19-22) | 21% (17-25) | 20% (18-23) | |
| At 12 m | 33% (31-35) | 31% (27-35) | 34% (31-37) |
| Outcome . | All patients . | CPI . | No prior CPI . | P value . |
|---|---|---|---|---|
| N = 2186 (95% CI) . | n = 600 (95% CI) . | n = 1586 (95% CI) . | ||
| OS | ||||
| At 100 d | 91% (89-92) | 89% (87-92) | 91% (90-93) | .439 |
| At 6 m | 85% (83-86) | 83% (79-86) | 86% (84-88) | |
| At 12 m | 78% (76-80) | 76% (73-80) | 79% (77-81) | |
| PFS | ||||
| At 100 d | 86% (84-87) | 87% (84-90) | 85% (83-87) | <.001 |
| At 6 m | 74% (72-76) | 78% (75-82) | 72% (70-75) | |
| At 12 m | 61% (58-63) | 69% (65-74) | 58% (55-60) | |
| CI of relapse | ||||
| At 100 d | 7% (6-9) | 4% (3-6) | 9% (7-10) | <.001 |
| At 6 m | 15% (13-17) | 8% (6-10) | 18% (16-20) | |
| At 12 m | 25% (23-27) | 13% (10-16) | 29% (27-32) | |
| NRM | ||||
| At 100 d | 7% (6-8) | 9% (6-11) | 6% (5-8) | .0277 |
| At 6 m | 11% (10-12) | 14% (11-17) | 10% (8-12) | |
| At 12 m | 15% (13-16) | 18% (14-21) | 13% (12-15) | |
| CI of engraftment | ||||
| At 30 d | 97% (96-97) | 96% (94-98) | 97% (96-98) | .3673 |
| At 100 d | 98% (98-99) | 98% (97-99) | 98% (98-99) | |
| aGVHD 2-4∗ | ||||
| At 30 d | 19% (18-21) | 26% (23-30) | 17% (15-19) | <.001 |
| At 100 d | 31% (29-33) | 40% (36-44) | 27% (25-30) | |
| aGVHD 3-4∗ | ||||
| At 30 d | 8% (6-9) | 12% (9-15) | 6% (5-7) | <.001 |
| At 100 d | 11% (10-13) | 16% (13-19) | 9% (8-11) | |
| cGVHD∗ | ||||
| At 100 d | 5% (4-6) | 5% (3-7) | 5% (4-7) | .1514 |
| At 6 m | 21% (19-22) | 21% (17-25) | 20% (18-23) | |
| At 12 m | 33% (31-35) | 31% (27-35) | 34% (31-37) |
Competition with relapse and death.